8-K: CytoSorbents' DrugSorb-ATR FDA Appeal Upheld

CytoSorbents Corporation announced the FDA upheld its De Novo denial for DrugSorb-ATR, citing a need for more information, but proposed a potential path forward for market authorization.

Summary

• The U.S. Food and Drug Administration (FDA) upheld its prior De Novo denial decision for CytoSorbents' DrugSorb-ATR.
• The FDA found no issues with DrugSorb-ATR device safety.
• The denial was based on the need for additional information to support the desired label indication for this FDA Breakthrough Device.
• The FDA proactively proposed a potential path forward for market authorization of DrugSorb-ATR.
• CytoSorbents is evaluating another avenue for appeal to the Director of the FDA's Center for Devices and Radiologic Health (CDRH), which must be filed within 30 days of the appeal decision.
• Health Canada issued a Notice of Refusal for the Medical Device License application for DrugSorb-ATR on June 26, 2025, identifying remaining deficiencies.
• CytoSorbents has filed a Level 1 Request for Reconsideration with Health Canada, with review to follow the completion of the U.S. FDA review.
• DrugSorb-ATR is an investigational device designed to reduce perioperative bleeding in high-risk surgery, specifically for CABG patients on ticagrelor.
• CytoSorb, the company's lead product, is approved in the European Union and distributed in over 70 countries, with nearly 300,000 devices used cumulatively.
• CytoSorb also has FDA Emergency Use Authorization in the United States for adult critically ill COVID-19 patients.

Sentiment

Score: 4

Explanation: While the FDA upheld its denial, the explicit statement of no safety issues and the proactive proposal of a 'path forward' offer a glimmer of hope, preventing a lower score. However, the Health Canada refusal is an additional setback, indicating continued regulatory hurdles and delays.

Positives

• The FDA found no issues with DrugSorb-ATR device safety, which is a critical component for regulatory approval.
• The FDA proactively proposed a potential path forward for market authorization, indicating continued engagement and a non-definitive rejection.
• Management believes significant progress has been made with the resolution of the majority of outstanding issues previously raised by the FDA.
• DrugSorb-ATR has received two FDA Breakthrough Device Designations, highlighting its potential clinical significance.

Negatives

• The FDA upheld its prior De Novo denial decision for DrugSorb-ATR, delaying market authorization in the U.S.
• Health Canada issued a Notice of Refusal for the Medical Device License application for DrugSorb-ATR, delaying market authorization in Canada.
• DrugSorb-ATR is not yet approved or cleared for commercialization in either the United States or Canada.

Risks

• Ability to resolve deficiencies in the FDA appeal decision and to identify a path forward for market authorization.
• Ability to resolve deficiencies in the Health Canada Notice of Refusal and/or successfully appeal Health Canada's decision.
• Risks discussed in the Annual Report on Form 10-K, filed with the SEC on March 31, 2025, as updated by Quarterly Reports on Form 10-Q.
• Restructuring of the direct sales team and strategy in Germany.

Future Outlook

Management is committed to continuing collaborative interaction with the FDA to bring DrugSorb-ATR to the U.S. market. The company plans to discuss the FDA's proactively proposed path forward for market authorization. Additionally, the company is evaluating another avenue for appeal to a higher level within the FDA (Director of CDRH) that must be filed within 30 days. For Canada, the company will pursue the Level 1 Request for Reconsideration with Health Canada following the completion of the U.S. FDA review.

Management Comments

• "The path to FDA approval frequently involves sequential, collaborative discussions with the Agency to address issues that arise during the review process."
• "Although we are disappointed that the denial decision was upheld, we believe significant progress has been made with the resolution of the majority of outstanding issues previously raised by the FDA."
• "Importantly, we have affirmed no issues of device safety on which the De Novo standard of a favorable benefit-to-risk profile is established."
• "We appreciate the Agencys offer to find a path forward to market authorization that we plan to discuss with them further."
• "We remain committed to continuing our collaborative interaction with the FDA to bring DrugSorb-ATR, an FDA Breakthrough Device, to the tens of thousands of heart attack patients in the U.S. each year who require urgent coronary artery bypass graft (CABG) surgery on ticagrelor."

Industry Context

The filing highlights the significant and growing clinical challenge of managing perioperative bleeding in patients on blood thinners, particularly those requiring urgent cardiac surgery. DrugSorb-ATR aims to address this unmet medical need, positioning CytoSorbents as a potential innovator in the blood purification and surgical support space. The company's existing product, CytoSorb, is already established globally for various critical illnesses, demonstrating a proven technology platform that could be leveraged for DrugSorb-ATR's eventual market entry.

Stakeholder Impact

• Shareholders face continued uncertainty and potential negative impact due to regulatory delays for a key product in the U.S. and Canada, though mitigated by the FDA's proposed path forward and no safety issues.
• Patients requiring urgent CABG surgery on ticagrelor in the U.S. and Canada will continue to experience delays in accessing DrugSorb-ATR, which aims to reduce severe perioperative bleeding.
• Medical professionals in the U.S. and Canada will continue to lack this specific device to manage perioperative bleeding risks in high-risk patients.

Next Steps

• Continue interactive discussions with the FDA to seek further clarity on the proposed path forward for market authorization of DrugSorb-ATR.
• Evaluate another avenue for appeal to the Director of the FDA's Center for Devices and Radiologic Health (CDRH) within 30 days of the appeal decision.
• Pursue the Level 1 Request for Reconsideration with Health Canada following the completion of the U.S. FDA review.

Key Dates

Recommendation

While the FDA upheld its denial, the explicit statement of no safety issues and the proactive proposal of a 'path forward' offer a glimmer of hope, suggesting the company is not at a dead end. However, the Health Canada refusal and the ongoing need for 'additional information' mean significant regulatory hurdles remain, introducing continued uncertainty and delays. Investors should hold to see how the proposed path forward with the FDA materializes and if the Health Canada appeal is successful, as these outcomes will dictate the commercialization timeline and potential revenue generation for DrugSorb-ATR. The existing CytoSorb business provides a base, but DrugSorb-ATR's U.S. and Canadian market entry is crucial for significant growth.

Keywords

CytoSorbents, CTSO, DrugSorb-ATR, FDA, De Novo, Medical Device, Blood Purification, Ticagrelor, CABG, Perioperative Bleeding, Health Canada, Breakthrough Device, CytoSorb